Production (Stage)
Apellis Pharmaceuticals, Inc.
APLS
$17.44
-$0.34-1.91%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -153.69% | 36.72% | -52.55% | 43.31% | 25.01% |
| Total Depreciation and Amortization | -0.22% | -2.19% | 1.78% | 1.13% | -6.72% |
| Total Amortization of Deferred Charges | 0.68% | -10.79% | 176.47% | 213.16% | 1.33% |
| Total Other Non-Cash Items | 4.03% | -4.23% | -21.07% | -4.41% | 11.39% |
| Change in Net Operating Assets | -63.32% | -54.94% | 1,118.95% | 94.03% | -143.28% |
| Cash from Operations | -375.88% | -43.22% | 508.87% | 93.73% | -35.87% |
| Capital Expenditure | 60.00% | -- | 100.00% | 69.28% | -208.42% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 60.00% | -- | 100.00% | 69.28% | -7,425.00% |
| Total Debt Issued | -- | -- | -100.00% | -- | -- |
| Total Debt Repaid | -- | -- | 200.00% | -- | -- |
| Issuance of Common Stock | -82.87% | -35.84% | -50.42% | -45.61% | -65.02% |
| Repurchase of Common Stock | 53.33% | -7.14% | -- | 100.00% | -1,300.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -254.00% | 99.51% | -430.62% | 418.59% |
| Cash from Financing | 106.85% | -257.36% | -94.02% | -60.74% | 2,865.45% |
| Foreign Exchange rate Adjustments | 137.20% | -657.80% | -49.42% | 263.64% | -135.79% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -467.20% | -60.95% | 7.01% | 236.11% | 75.03% |